José Díez, MD

Dr. José G. Díez er certificeret specialist i hjerte-kar-sygdomme og interventionel kardiologi. Han er seniorforsker i interventionel kardiologi ved The Texas Heart Institute på CHI Baylor St Luke's Medical Center (BSLMC) og klinisk lektor i medicin ved Baylor College of Medicine i Houston, Texas.

Vis hele bio

Han er på det professionelle personale i interventionel kardiologi hos THI ved BSLMC og konsulentpersonalet i kardiologitjenesten på Texas Children's Hospital i Houston. Dr. Díez er også associeret redaktør af Texas Heart Institute Journal. Dr. Díez, som er uddannet fra Javeriana University i Bogotá, Colombia, afsluttede et internt medicinophold ved samme institution og et andet ved Boston University i Massachusetts.

Dr. Díez afsluttede sin uddannelse i hjerte-kar-sygdomme og interventionel kardiologi på The Texas Heart Institute på St. Luke's Episcopal Hospital, hvor han fungerede som chief fellow. Hans tidligere akademiske erfaring omfatter udnævnelser på Baylor College of Medicine som direktør for invasiv kardiologi på Baylor Heart Clinic og direktør for interventionel kardiologisk forskning.

På Tulane University School of Medicine i New Orleans, Louisiana, fungerede han som direktør for klinisk og interventionel forskning og meddirektør for de kardiovaskulære kateteriseringslaboratorier. Han har modtaget forsknings- og uddannelsespriser fra Mueller Foundation, EVEREST-programmet, American College of Cardiology og American Heart Association.

Hans interesser omfatter akutte koronare syndromer; akutte og kroniske aortasyndromer (aortaaneurismer, aortadissektion, Marfans syndrom); klapsygdom (med fokus på aortaklappen og nye terapier, såsom transkateter aortaklapimplantation TAVI/TAVR); atherotrombose; antiblodplade- og antitrombinterapi; interventionelle strategier og anordninger; og vaskulær biologi. Dr. Díez taler flydende både engelsk og spansk. Han accepterer i øjeblikket nye patienter, herunder dem, der søger at begynde kardiovaskulær behandling og behandling, og dem, der søger sekundære udtalelser og konsultationer.

Skjul hele bio

Se Publikationer

Texas Heart Institute-stillinger

Undervisningspersonale, Hjerte-kar-sygdomsfællesskab
Associeret redaktør, Texas Heart Institute Journal

Interesser

Interventionel kardiologi
akutte koronare syndromer
antiblodplade- og antitrombinbehandlinger

Uddannelse

Medicin skole:

Pavelige Xavierian Universitet
Bopæl:

Caritas Carney Hospital
stipendier:

Baylor College of Medicine

Akademiske og kliniske tilhørsforhold

Baylor College of Medicine
Baylor St. Luke's Medical Center
Texas børnehospital
Park Plaza Hospital
Hall-Garcia Cardiology ved Baylor College of Medicine

Specifikationer

Kardiovaskulær sygdom, American Board of Internal Medicine
Interventionel kardiologi, American Board of Internal Medicine
Internal Medicine, American Board of Internal Medicine

Hæder, priser og medlemskaber

American College of Cardiology Interventional Scientific Council og sektion
Texas Heart Institute Academic Professional Staff

Publikationer

4862227 YL3LPZGE 1 alternativer til dyreforsøg 10 dato desc 1887 https://www.texasheart.org/wp-content/plugins/zotpress/

%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22D7KQKNXR%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hong%20et%20al.%22%2C%22parsedDate%22%3A%222023-03-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BHong%2C%20J.%20C.%2C%20Orozco-Sevilla%2C%20V.%2C%20Diez%2C%20J.%20G.%20et%20al.%20%282023%29.%20Transcatheter%20aortic%20valve-in-valve-in-valve%20replacement%20in%20a%20young%20woman%20with%20transcatheter%20structural%20valve%20deterioration%20within%20a%20degenerated%20aortic%20root%20homograft.%20%26lt%3Bi%26gt%3BTex%20Heart%20Inst%20J%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B50%26lt%3B%5C%2Fi%26gt%3B%2C%20e227874.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.14503%5C%2FTHIJ-22-7874%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.14503%5C%2FTHIJ-22-7874%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Transcatheter%20aortic%20valve-in-valve-in-valve%20replacement%20in%20a%20young%20woman%20with%20transcatheter%20structural%20valve%20deterioration%20within%20a%20degenerated%20aortic%20root%20homograft%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%20C.%22%2C%22lastName%22%3A%22Hong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vicente%22%2C%22lastName%22%3A%22Orozco-Sevilla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20G.%22%2C%22lastName%22%3A%22Diez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20S.%22%2C%22lastName%22%3A%22Coselli%22%7D%5D%2C%22abstractNote%22%3A%22Transcatheter%20aortic%20valve%20replacement%20is%20a%20well-established%20procedure%20for%20older%20patients%20with%20symptomatic%2C%20severe%20aortic%20stenosis.%20However%2C%20data%20are%20lacking%20on%20its%20durability%20and%20long-term%20complications%2C%20particularly%20in%20young%20patients%20and%20patients%20treated%20for%20aortic%20valve%20regurgitation.%20This%20article%20describes%20the%20case%20of%20a%2027-year-old%20woman%20with%20complex%20congenital%20cardiovascular%20disease%20who%2C%20after%204%20previous%20aortic%20valve%20replacement%20procedures%2C%20presented%20with%20structural%20deterioration%20of%20her%20most%20recent%20replacement%20valve%2C%20which%20had%20been%20placed%20by%20transcatheter%20aortic%20valve%20replacement%20inside%20a%20failed%20aortic%20root%20homograft%206%20years%20earlier.%20After%20the%20patient%20had%20undergone%20this%20transcatheter%20aortic%20valve%20replacement%20procedure%20to%20treat%20aortic%20valve%20regurgitation%20related%20to%20her%20degenerated%20aortic%20root%20homograft%2C%20she%20became%20pregnant%20and%20successfully%20carried%20her%20high-risk%20pregnancy%20to%20term.%20However%2C%20the%20replacement%20valve%20deteriorated%20during%20the%20late%20stages%20of%20pregnancy%2C%20resulting%20in%20substantial%20hemodynamic%20changes%20between%20the%20first%20trimester%20and%20the%20postpartum%20period.%20To%20avoid%20repeat%20sternotomy%2C%20a%20redo%20transcatheter%20valve-in-valve%20replacement%20procedure%20procedure%20was%20performed%20through%20the%20right%20carotid%20artery.%20Because%20the%20patient%20wanted%20to%20have%20more%20children%20and%20therefore%20avoid%20anticoagulation%2C%20a%20SAPIEN%203%20transcatheter%20valve%20%28Edwards%20Lifesciences%29%20was%20placed%20as%20a%20bridge%20to%20a%20future%2C%20more-durable%20aortic%20root%20replacement.%20The%20result%20in%20this%20case%20suggests%20that%20in%20patients%20with%20complex%20adult%20congenital%20pathology%2C%20transcatheter%20aortic%20valve%20replacement%20can%20be%20used%20as%20a%20temporizing%20bridge%20to%20subsequent%2C%20definitive%20aortic%20valve%20repair.%22%2C%22date%22%3A%222023-03-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.14503%5C%2FTHIJ-22-7874%22%2C%22ISSN%22%3A%221526-6702%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22BJSZ96GT%22%2C%22YL3LPZGE%22%2C%22KRWEJ8EU%22%2C%22BNSCCUCI%22%5D%2C%22dateModified%22%3A%222023-06-08T14%3A18%3A17Z%22%7D%7D%2C%7B%22key%22%3A%223Y2JRUSY%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Farmer%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFarmer%2C%20D.%20M.%2C%20D%26%23xED%3Bez%2C%20J.%20G.%2C%20Orozco-Sevilla%2C%20V.%20et%20al.%20%282022%29.%20Use%20of%20a%20self-expanding%20transcatheter%20valve%20for%20a%20degenerated%20INTUITY%20valve.%20%26lt%3Bi%26gt%3BJ%20Card%20Surg%26lt%3B%5C%2Fi%26gt%3B.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fjocs.16746%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fjocs.16746%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Use%20of%20a%20self-expanding%20transcatheter%20valve%20for%20a%20degenerated%20INTUITY%20valve%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Douglas%20M.%22%2C%22lastName%22%3A%22Farmer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20G.%22%2C%22lastName%22%3A%22D%5Cu00edez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vicente%22%2C%22lastName%22%3A%22Orozco-Sevilla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20S.%22%2C%22lastName%22%3A%22Coselli%22%7D%5D%2C%22abstractNote%22%3A%22Valve-in-valve%20transcatheter%20aortic%20valve%20replacement%20for%20degenerated%20surgical%20bioprosthesis%20is%20becoming%20a%20more%20common%20therapeutic%20option.%20Rapid-deployment%20valves%20are%20novel%2C%20have%20distinct%20structural%20differences%20from%20standard%20surgical%20valves%2C%20and%20are%20increasingly%20used%20in%20minimal-access%20surgery.%20We%20report%20the%20case%20of%20a%2061-year-old%20man%20who%20developed%20severe%20stenosis%20of%20an%20Edwards%20INTUITY%20Elite%20rapid-deployment%20valve%20and%20who%20subsequently%20underwent%20successful%20valve-in-valve%20placement%20of%20a%20self-expanding%20transcatheter%20valve.%20To%20our%20knowledge%2C%20this%20is%20the%20first%20description%20of%20the%20technical%20aspects%20of%20and%20considerations%20for%20using%20the%20self-expanding%20transcatheter%20platform%20in%20the%20Edwards%20INTUITY%20Elite%20valve.%22%2C%22date%22%3A%22July%2011%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fjocs.16746%22%2C%22ISSN%22%3A%221540-8191%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22BJSZ96GT%22%2C%22YL3LPZGE%22%2C%22KRWEJ8EU%22%2C%222RCWVZ4F%22%5D%2C%22dateModified%22%3A%222022-08-02T14%3A43%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22EFZ9YY7A%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kherallah%20et%20al.%22%2C%22parsedDate%22%3A%222021-09%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BKherallah%2C%20R.%20Y.%2C%20Koneru%2C%20S.%2C%20Krajcer%2C%20Z.%20et%20al.%20%282021%29.%20Hemodynamic%20outcomes%20after%20valve-in-valve%20transcatheter%20aortic%20valve%20replacement%3A%20a%20single-center%20experience.%20%26lt%3Bi%26gt%3BAnn%20Cardiothorac%20Surg%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B10%26lt%3B%5C%2Fi%26gt%3B%2C%20630%26%23x2013%3B640.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.21037%5C%2Facs-2021-tviv-131%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.21037%5C%2Facs-2021-tviv-131%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Hemodynamic%20outcomes%20after%20valve-in-valve%20transcatheter%20aortic%20valve%20replacement%3A%20a%20single-center%20experience%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20Yazan%22%2C%22lastName%22%3A%22Kherallah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Srikanth%22%2C%22lastName%22%3A%22Koneru%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zvonimir%22%2C%22lastName%22%3A%22Krajcer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ourania%22%2C%22lastName%22%3A%22Preventza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%20G.%22%2C%22lastName%22%3A%22Dougherty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melissa%20L.%22%2C%22lastName%22%3A%22McCormack%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Briana%20T.%22%2C%22lastName%22%3A%22Costello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephanie%22%2C%22lastName%22%3A%22Coulter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neil%20E.%22%2C%22lastName%22%3A%22Strickman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Carlos%22%2C%22lastName%22%3A%22Plana%20Gomez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ali%22%2C%22lastName%22%3A%22Mortazavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20G.%22%2C%22lastName%22%3A%22D%5Cu00edez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20J.%22%2C%22lastName%22%3A%22Livesay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20S.%22%2C%22lastName%22%3A%22Coselli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guilherme%20V.%22%2C%22lastName%22%3A%22Silva%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Sept%202021%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.21037%5C%2Facs-2021-tviv-131%22%2C%22ISSN%22%3A%222225319X%2C%2023041021%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.annalscts.com%5C%2Farticle%5C%2Fview%5C%2F16858%5C%2Fhtml%22%2C%22collections%22%3A%5B%22DV9ZHE2J%22%2C%223WHLRQCH%22%2C%22SQD2CTYV%22%2C%22BJSZ96GT%22%2C%22YL3LPZGE%22%2C%22Z2XX7DHR%22%2C%22M32R8FP2%22%2C%22YQ6XGPLC%22%2C%22RB8ZRZCJ%22%2C%222K4N54U2%22%2C%22QSVIJDTT%22%2C%22MZXU6P62%22%2C%228PULYTSK%22%5D%2C%22dateModified%22%3A%222022-05-12T20%3A43%3A50Z%22%7D%7D%2C%7B%22key%22%3A%22AEDTA97A%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cekmecelioglu%20et%20al.%22%2C%22parsedDate%22%3A%222021-09%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCekmecelioglu%2C%20D.%2C%20Preventza%2C%20O.%2C%20Dougherty%2C%20K.%20G.%20et%20al.%20%282021%29.%20Transcatheter%20valve-in-valve%20implantation%20for%20degenerated%20stentless%20aortic%20bioroots.%20%26lt%3Bi%26gt%3BAnn%20Cardiothorac%20Surg%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B10%26lt%3B%5C%2Fi%26gt%3B%2C%20641%26%23x2013%3B650.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.21037%5C%2Facs-2021-tviv-124%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.21037%5C%2Facs-2021-tviv-124%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Transcatheter%20valve-in-valve%20implantation%20for%20degenerated%20stentless%20aortic%20bioroots%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Davut%22%2C%22lastName%22%3A%22Cekmecelioglu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ourania%22%2C%22lastName%22%3A%22Preventza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%20G.%22%2C%22lastName%22%3A%22Dougherty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Subhasis%22%2C%22lastName%22%3A%22Chatterjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susan%20Y.%22%2C%22lastName%22%3A%22Green%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guilherme%20V.%22%2C%22lastName%22%3A%22Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20G.%22%2C%22lastName%22%3A%22D%5Cu00edez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20S.%22%2C%22lastName%22%3A%22Coselli%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%20Open%20surgical%20repair%20of%20a%20failed%20valve-sparing%20aortic%20root%20replacement%20%28VSARR%29%20or%20stentless%20bioroot%20aortic%20root%20replacement%20%28bio-ARR%29%20entails%20significant%20operative%20risks.%20Whether%20valve-in-valve%20transcatheter%20aortic%20valve%20replacement%20%28ViV-TAVR%29%20is%20feasible%20in%20patients%20with%20a%20previous%20VSARR%20or%20stentless%20bio-ARR%20remains%20unclear%2C%20given%20lingering%20concerns%20about%20the%20ill-defined%20aortic%20annulus%20in%20these%20patients%20and%20the%20potential%20for%20coronary%20obstruction.%20We%20present%20our%20experience%20with%20patients%20who%20had%20a%20previous%20VSARR%20or%20stentless%20bio-ARR%20and%20underwent%20ViV-TAVR%20to%20repair%20a%20degenerated%20aortic%20valve%20with%20combined%20valvular%20disease%2C%20aortic%20insufficiency%20and%20aortic%20stenosis.%5CnMethods%3A%20In%20this%20retrospective%20data%20review%2C%20we%20identified%20and%20analyzed%20consecutive%20patients%20with%20a%20previous%20VSARR%20or%20stentless%20bio-ARR%20who%20underwent%20ViV-TAVR%20between%20December%201%2C%202014%20and%20August%2031%2C%202019.%5CnResults%3A%20ViV-TAVR%20was%20performed%20in%20twelve%20high-risk%20patients%20with%20previous%20VSARR%20or%20bio-ARR%20during%20the%20study%20period.%20Of%20these%2C%20seven%20received%20Medtronic%20Freestyle%20porcine%20stentless%20bioprosthetic%20aortic%20roots%2C%20three%20received%20homograft%20aortic%20roots%2C%20one%20underwent%20a%20Ross%20procedure%20and%20one%20underwent%20VSARR.%20ViV-TAVR%20restored%20satisfactory%20valve%20function%20in%20all%20patients%2C%20and%20technical%20success%20was%20100%25.%20No%20patient%20had%20more%20than%20mild%20regurgitation%20after%20implantation.%20No%20thirty-day%20mortality%20was%20seen.%20One%20patient%20had%20major%20bleeding%20after%20transapical%20access%2C%20one%20patient%20had%20a%20transient%20ischemic%20stroke%2C%20and%20one%20patient%20needed%20permanent%20pacemaker%20implantation.%20At%20a%20median%20last%20follow-up%20of%2021.5%20months%20%28interquartile%20range%2C%209.0-69.0%20months%29%2C%20all%20patients%20remained%20alive%20and%20had%20satisfactory%20valve%20function.%5CnConclusions%3A%20In%20this%20study%2C%20ViV-TAVR%20was%20a%20clinically%20effective%20option%20for%20treating%20patients%20with%20a%20failed%20stentless%20bio-ARR%20or%20previous%20VSARR.%20Short-term%20and%20intermediate-term%20results%20after%20these%20procedures%20were%20favorable.%20These%20findings%20may%20have%20important%20implications%20for%20treating%20high-risk%20patients%20with%20structural%20aortic%20root%20deterioration%20and%20call%20for%20better%20transcatheter%20heart%20valves%20that%20are%20suitable%20for%20treating%20aortic%20insufficiency.%22%2C%22date%22%3A%222021-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.21037%5C%2Facs-2021-tviv-124%22%2C%22ISSN%22%3A%222225-319X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22YL3LPZGE%22%5D%2C%22dateModified%22%3A%222022-01-25T18%3A46%3A50Z%22%7D%7D%2C%7B%22key%22%3A%22JPZNHSX4%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kleiman%20et%20al.%22%2C%22parsedDate%22%3A%222016-09%22%2C%22numChildren%22%3A6%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BKleiman%2C%20N.%20S.%2C%20Maini%2C%20B.%20J.%2C%20Reardon%2C%20M.%20J.%20et%20al.%20%282016%29.%20Neurological%20events%20following%20transcatheter%20aortic%20valve%20replacement%20and%20their%20predictors%3A%20a%20report%20from%20the%20corevalve%20trials.%20%26lt%3Bi%26gt%3BCirc%20Cardiovasc%20Interv%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B9%26lt%3B%5C%2Fi%26gt%3B.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FCIRCINTERVENTIONS.115.003551%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FCIRCINTERVENTIONS.115.003551%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Neurological%20events%20following%20transcatheter%20aortic%20valve%20replacement%20and%20their%20predictors%3A%20a%20report%20from%20the%20corevalve%20trials%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neal%20S.%22%2C%22lastName%22%3A%22Kleiman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brijeshwar%20J.%22%2C%22lastName%22%3A%22Maini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20J.%22%2C%22lastName%22%3A%22Reardon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Conte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stanley%22%2C%22lastName%22%3A%22Katz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vivek%22%2C%22lastName%22%3A%22Rajagopal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%22%2C%22lastName%22%3A%22Kauten%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alan%22%2C%22lastName%22%3A%22Hartman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raymond%22%2C%22lastName%22%3A%22McKay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Hagberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jian%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%22%2C%22lastName%22%3A%22Popma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22CoreValve%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20risk%20for%20stroke%20after%20transcatheter%20aortic%20valve%20replacement%20%28TAVR%29%20is%20an%20important%20concern.%20Identification%20of%20predictors%20for%20stroke%20is%20likely%20to%20be%20a%20critical%20factor%20aiding%20patient%20selection%20and%20management%20as%20TAVR%20use%20becomes%20widespread.%5CnMETHODS%20AND%20RESULTS%3A%20Patients%20enrolled%20in%20the%20CoreValve%20US%20Extreme%20Risk%20and%20High%20Risk%20Pivotal%20Trials%20or%20Continued%20Access%20Study%20treated%20with%20the%20self-expanding%20CoreValve%20bioprosthesis%20were%20included%20in%20this%20analysis.%20The%201-year%20stroke%20rate%20after%20TAVR%20was%208.4%25.%20Analysis%20of%20the%20stroke%20hazard%20rate%20identified%20an%20early%20phase%20%280-10%20days%3B%204.1%25%20of%20strokes%29%20and%20a%20late%20phase%20%2811-365%20days%3B%204.3%25%20of%20strokes%29.%20Baseline%20predictors%20of%20early%20stroke%20included%20National%20Institutes%20of%20Health%20stroke%20scale%20score%20%26gt%3B0%2C%20prior%20stroke%2C%20prior%20transient%20ischemic%20attack%2C%20peripheral%20vascular%20disease%2C%20absence%20of%20prior%20coronary%20artery%20bypass%20surgery%2C%20angina%2C%20low%20body%20mass%20index%20%28%26lt%3B21%20kg%5C%2Fm%282%29%29%2C%20and%20falls%20within%20the%20past%206%20months.%20Significant%20procedural%20predictors%20were%20total%20time%20in%20the%20catheterization%20laboratory%20or%20operating%20room%2C%20delivery%20catheter%20in%20the%20body%20time%2C%20rapid%20pacing%20used%20during%20valvuloplasty%2C%20and%20repositioning%20of%20the%20prosthesis.%20Predictors%20of%20stroke%20between%2011%20and%20365%20days%20were%20small%20body%20surface%20area%2C%20severe%20aortic%20calcification%2C%20and%20falls%20within%20the%20past%206%20months.%20There%20were%20no%20significant%20imaging%20predictors%20of%20early%20or%20late%20stroke.%5CnCONCLUSIONS%3A%20Predictors%20of%20early%20stroke%20after%20TAVR%20included%20clinical%20and%20procedural%20factors%3B%20predictors%20of%20later%20stroke%20were%20limited%20to%20patient%20but%20not%20anatomic%20characteristics.%20These%20findings%20indicate%20that%20further%20refinement%20of%20imaging%20to%20identify%20anatomic%20factors%20predisposing%20to%20embolization%20may%20help%20improve%20stroke%20prediction%20in%20patients%20undergoing%20TAVR.%5CnCLINICAL%20TRIAL%20REGISTRATIONS%3A%20URL%3A%20http%3A%5C%2F%5C%2Fwww.clinicaltrials.gov.%20Unique%20identifiers%3A%20NCT01240902%2C%20NCT01531374.%22%2C%22date%22%3A%22Sep%202016%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCINTERVENTIONS.115.003551%22%2C%22ISSN%22%3A%221941-7632%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22BJSZ96GT%22%2C%22YL3LPZGE%22%5D%2C%22dateModified%22%3A%222022-01-25T19%3A49%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22GR2C5DCX%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22D%5Cu00edez%20et%20al.%22%2C%22parsedDate%22%3A%222016-08%22%2C%22numChildren%22%3A7%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BD%26%23xED%3Bez%2C%20J.%20G.%2C%20Schechter%2C%20M.%2C%20Dougherty%2C%20K.%20G.%20et%20al.%20%282016%29.%20Transcatheter%20aortic%20valve-in-valve%20replacement%20instead%20of%20a%204th%20sternotomy%20in%20a%2021-year-old%20woman%20with%20aortic%20homograft%20failure.%20%26lt%3Bi%26gt%3BTex%20Heart%20Inst%20J%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B43%26lt%3B%5C%2Fi%26gt%3B%2C%20334%26%23x2013%3B337.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.14503%5C%2FTHIJ-15-5128%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.14503%5C%2FTHIJ-15-5128%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Transcatheter%20aortic%20valve-in-valve%20replacement%20instead%20of%20a%204th%20sternotomy%20in%20a%2021-year-old%20woman%20with%20aortic%20homograft%20failure%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20G.%22%2C%22lastName%22%3A%22D%5Cu00edez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Schechter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%20G.%22%2C%22lastName%22%3A%22Dougherty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ourania%22%2C%22lastName%22%3A%22Preventza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20S.%22%2C%22lastName%22%3A%22Coselli%22%7D%5D%2C%22abstractNote%22%3A%22Transcatheter%20aortic%20valve%20replacement%20%28TAVR%29%20is%20a%20well-established%20method%20for%20replacing%20native%20aortic%20valves%3B%20however%2C%20it%20was%20conceived%20for%20elderly%20patients%20with%20aortic%20valve%20stenosis%2C%20and%20the%20lack%20of%20data%20on%20long-term%20durability%20has%20led%20practitioners%20to%20restrict%20the%20use%20of%20TAVR%20to%20patients%20who%20have%20short%20life%20expectancies.%20Here%2C%20we%20describe%20the%20case%20of%20a%2021-year-old%20woman%20who%20had%20undergone%203%20previous%20open%20aortic%20valve%20replacements%20and%20who%20presented%20with%20symptoms%20of%20recurrent%20valvular%20failure.%20Transthoracic%20echocardiograms%20and%20computed%20tomographic%20angiograms%20revealed%20a%20degenerating%20aortic%20root%20homograft%20with%20substantial%20calcification%2C%20moderate-to-severe%20aortic%20valve%20stenosis%2C%20and%20severe%20aortic%20valve%20regurgitation.%20Open%20surgical%20valve%20replacement%20posed%20substantial%20risk%20to%20our%20patient%2C%20so%20we%20decided%20to%20perform%20valve-in-valve%20TAVR%20with%20use%20of%20the%20Edwards%20Sapien%20XT%20Transcatheter%20Heart%20Valve.%20The%20patient%26%23039%3Bs%20pulmonary%20artery%20pressure%2C%20valvular%20regurgitation%2C%20and%20symptoms%20improved%20substantially%20thereafter.%20We%20found%20that%20valve-in-valve%20TAVR%20into%20a%20failing%20aortic%20root%20homograft%20was%20less%20invasive%20than%20repeat%20surgical%20valve%20replacement%20in%20this%20young%20patient%20who%20had%20congenital%20vascular%20anomalies%20and%20a%20complex%20surgical%20history.%22%2C%22date%22%3A%22Aug%202016%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.14503%5C%2FTHIJ-15-5128%22%2C%22ISSN%22%3A%221526-6702%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SQD2CTYV%22%2C%22BJSZ96GT%22%2C%22YL3LPZGE%22%5D%2C%22dateModified%22%3A%222022-01-25T18%3A51%3A07Z%22%7D%7D%2C%7B%22key%22%3A%228XFH9SJ9%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Yakubov%20et%20al.%22%2C%22parsedDate%22%3A%222015-09-22%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BYakubov%2C%20S.%20J.%2C%20Adams%2C%20D.%20H.%2C%20Watson%2C%20D.%20R.%20et%20al.%20%282015%29.%202-Year%20Outcomes%20After%20Iliofemoral%20Self-Expanding%20Transcatheter%20Aortic%20Valve%20Replacement%20in%20Patients%20With%20Severe%20Aortic%20Stenosis%20Deemed%20Extreme%20Risk%20for%20Surgery.%20%26lt%3Bi%26gt%3BJ%20Am%20Coll%20Cardiol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B66%26lt%3B%5C%2Fi%26gt%3B%2C%201327%26%23x2013%3B1334.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacc.2015.07.042%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacc.2015.07.042%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%222-Year%20Outcomes%20After%20Iliofemoral%20Self-Expanding%20Transcatheter%20Aortic%20Valve%20Replacement%20in%20Patients%20With%20Severe%20Aortic%20Stenosis%20Deemed%20Extreme%20Risk%20for%20Surgery%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%20J.%22%2C%22lastName%22%3A%22Yakubov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20H.%22%2C%22lastName%22%3A%22Adams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%20R.%22%2C%22lastName%22%3A%22Watson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20J.%22%2C%22lastName%22%3A%22Reardon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neal%20S.%22%2C%22lastName%22%3A%22Kleiman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Heimansohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%22%2C%22lastName%22%3A%22Hermiller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20Chad%22%2C%22lastName%22%3A%22Hughes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Kevin%22%2C%22lastName%22%3A%22Harrison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Coselli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%22%2C%22lastName%22%3A%22Diez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Theodore%22%2C%22lastName%22%3A%22Schreiber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20G.%22%2C%22lastName%22%3A%22Gleason%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Conte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20Michael%22%2C%22lastName%22%3A%22Deeb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jian%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jae%22%2C%22lastName%22%3A%22Oh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%22%2C%22lastName%22%3A%22Byrne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Caskey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20J.%22%2C%22lastName%22%3A%22Popma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22CoreValve%20United%20States%20Clinical%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20We%20reported%20favorable%201-year%20outcomes%20in%20patients%20unsuitable%20for%20surgery%20who%20underwent%20self-expanding%20transcatheter%20aortic%20valve%20replacement%20%28TAVR%29%20compared%20with%20an%20objective%20performance%20goal.%20Longer-term%20outcomes%20in%20these%20patients%20are%20not%20known.%5CnOBJECTIVES%3A%20This%20study%20sought%20to%20evaluate%20the%202-year%20safety%20and%20efficacy%20in%20patients%20with%20severe%20aortic%20stenosis%20%28AS%29%20at%20extreme%20risk%20of%20surgery%20treated%20with%20self-expanding%20TAVR.%5CnMETHODS%3A%20We%20performed%20a%20prospective%2C%20multicenter%2C%20controlled%2C%20nonrandomized%20investigation%20of%20self-expanding%20TAVR%20in%20patients%20with%20severe%20AS%20and%20prohibitive%20surgical%20risk.%20We%20report%20the%202-year%20clinical%20outcomes%20in%20these%20patients.%5CnRESULTS%3A%20A%20total%20of%20489%20extreme-risk%20patients%20were%20treated%20transfemorally%20with%20a%20self-expanding%20aortic%20bioprosthesis%20at%2041%20centers.%20The%20rate%20of%20all-cause%20mortality%20or%20major%20stroke%20was%2038.0%25%20at%202%20years%20%28all-cause%20mortality%2C%2036.5%25%3B%20major%20stroke%2C%205.1%25%29.%20The%20rates%20of%20all-cause%20mortality%2C%20cardiovascular%20mortality%2C%20and%20major%20stroke%20were%2036.6%25%2C%2026.2%25%2C%20and%205.1%25%2C%20respectively%2C%20at%202%20years.%20Between%201%20and%202%20years%2C%20the%20incremental%20all-cause%20mortality%2C%20cardiovascular%20mortality%2C%20and%20major%20stroke%20rates%20were%2012.3%25%2C%207.9%25%2C%20and%200.8%25%2C%20respectively.%20Multivariable%20predictors%20of%20all-cause%20mortality%20at%202%20years%20included%20the%20presence%20of%20coronary%20artery%20disease%20and%20admission%20from%20an%20assisted%20living%20center.%20A%20Society%20of%20Thoracic%20Surgeons%20score%20%26gt%3B15%25%20was%20also%20predictive%20of%202-year%20all-cause%20mortality.%20At%202%20years%2C%2094%25%20of%20patients%20had%20New%20York%20Heart%20Association%20functional%20class%20I%20or%20II%20symptoms.%20The%20frequency%20of%20moderate%20or%20severe%20paravalvular%20regurgitation%20%284.3%25%20at%201%20year%3B%204.4%25%20at%202%20years%29%20was%20unchanged%20between%20the%20first%20and%20second%20year.%5CnCONCLUSIONS%3A%20Patients%20with%20severe%20AS%20at%20extreme%20surgical%20risk%20treated%20with%20self-expanding%20TAVR%20continued%20to%20show%20good%20clinical%20outcomes%20and%20hemodynamic%20valve%20performance%20at%202%20years.%20The%20presence%20of%20comorbid%20conditions%20rather%20than%20valve%20performance%20affected%202-year%20outcomes%20in%20these%20patients.%20%28Safety%20and%20Efficacy%20Study%20of%20the%20Medtronic%20CoreValve%20System%20in%20the%20Treatment%20of%20Symptomatic%20Severe%20Aortic%20Stenosis%20in%20High%20Risk%20and%20Very%20High%20Risk%20Subjects%20Who%20Need%20Aortic%20Valve%20Replacement%3B%20NCT01240902%29.%22%2C%22date%22%3A%22Sep%2022%2C%202015%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jacc.2015.07.042%22%2C%22ISSN%22%3A%221558-3597%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22BJSZ96GT%22%2C%22YL3LPZGE%22%5D%2C%22dateModified%22%3A%222022-01-25T18%3A51%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22F2DA4S4F%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lombo%20et%20al.%22%2C%22parsedDate%22%3A%222015-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLombo%2C%20B.%2C%20Alkhalil%2C%20I.%2C%20Golden%2C%20M.%20P.%20et%20al.%20%282015%29.%20Prevalence%20of%20metabolic%20syndrome%20in%20patients%20with%20HIV%20in%20the%20era%20of%20highly%20active%20antiretroviral%20therapy.%20%26lt%3Bi%26gt%3BConn%20Med%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B79%26lt%3B%5C%2Fi%26gt%3B%2C%20277%26%23x2013%3B281%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prevalence%20of%20metabolic%20syndrome%20in%20patients%20with%20HIV%20in%20the%20era%20of%20highly%20active%20antiretroviral%20therapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernardo%22%2C%22lastName%22%3A%22Lombo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Imran%22%2C%22lastName%22%3A%22Alkhalil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marjorie%20P.%22%2C%22lastName%22%3A%22Golden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Irma%22%2C%22lastName%22%3A%22Fotjadhi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sreedhar%22%2C%22lastName%22%3A%22Ravi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Virata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marta%22%2C%22lastName%22%3A%22Lievano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%22%2C%22lastName%22%3A%22Diez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andre%22%2C%22lastName%22%3A%22Ghantous%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Donohue%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20Since%20the%20introduction%20of%20combination%20antiretroviral%20therapy%20%28cART%29%20as%20the%20standard%20of%20care%20for%20HIV%20disease%2C%20there%20has%20been%20a%20precipitous%20decline%20in%20the%20death%20rate%20due%20to%20HIV%5C%2F%20AIDS.%20The%20purpose%20of%20this%20study%20was%20to%20report%20the%20prevalence%20of%20metabolic%20syndrome%20in%20HIV%20infected%20patients.%5CnMETHODS%3A%20Retrospective%2C%20cross-sectional%2C%20observational%20study%20of%20259%20patients%20with%20HIV%20infection%20treated%20with%20cART%20from%20an%20urban%20community%20hospital.%20Metabolic%20syndrome%20prevalence%20was%20defined%20using%20the%20International%20Diabetes%20Federation%20%28IDF%29%20and%20the%20U.S.%20National%20Cholesterol%20Education%20Program%20Adult%20Treatment%20Panel%20III%20%28ATP%20III%29%20criteria.%20Study%20patients%20were%20included%20regardless%20of%20the%20duration%20of%20cART.%5CnRESULTS%3A%20The%20prevalence%20of%20metabolic%20syndrome%20was%2027%25%20using%20IDF%20criteria%20and%2026%25%20using%20ATP%20III%20criteria.%20Logistic%20regression%20analysis%20found%20an%20association%20between%20treatment%20with%20the%20protease%20inhibitor%20darunavir%20and%20metabolic%20syndrome.%20%28OR%203.32%20with%2095%25%20confidence%20interval%20between%201.54%20and%207.15%29.%5CnCONCLUSION%3A%20There%20is%20a%20high%20prevalence%20of%20metabolic%20syndrome%20and%20obesity%20in%20HIV%20patients%20treated%20with%20cART%2C%20especially%20those%20taking%20the%20protease%20inhibitor%20darunavir.%22%2C%22date%22%3A%22May%202015%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%220010-6178%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22YL3LPZGE%22%5D%2C%22dateModified%22%3A%222022-01-25T18%3A55%3A58Z%22%7D%7D%2C%7B%22key%22%3A%22TSBBDPJ2%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Popma%20et%20al.%22%2C%22parsedDate%22%3A%222014-05-20%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPopma%2C%20J.%20J.%2C%20Adams%2C%20D.%20H.%2C%20Reardon%2C%20M.%20J.%20et%20al.%20%282014%29.%20Transcatheter%20aortic%20valve%20replacement%20using%20a%20self-expanding%20bioprosthesis%20in%20patients%20with%20severe%20aortic%20stenosis%20at%20extreme%20risk%20for%20surgery.%20%26lt%3Bi%26gt%3BJ%20Am%20Coll%20Cardiol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B63%26lt%3B%5C%2Fi%26gt%3B%2C%201972%26%23x2013%3B1981.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacc.2014.02.556%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacc.2014.02.556%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Transcatheter%20aortic%20valve%20replacement%20using%20a%20self-expanding%20bioprosthesis%20in%20patients%20with%20severe%20aortic%20stenosis%20at%20extreme%20risk%20for%20surgery%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20J.%22%2C%22lastName%22%3A%22Popma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20H.%22%2C%22lastName%22%3A%22Adams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20J.%22%2C%22lastName%22%3A%22Reardon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%20J.%22%2C%22lastName%22%3A%22Yakubov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neal%20S.%22%2C%22lastName%22%3A%22Kleiman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Heimansohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%22%2C%22lastName%22%3A%22Hermiller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20Chad%22%2C%22lastName%22%3A%22Hughes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Kevin%22%2C%22lastName%22%3A%22Harrison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Coselli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%22%2C%22lastName%22%3A%22Diez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ali%22%2C%22lastName%22%3A%22Kafi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Theodore%22%2C%22lastName%22%3A%22Schreiber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20G.%22%2C%22lastName%22%3A%22Gleason%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Conte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maurice%22%2C%22lastName%22%3A%22Buchbinder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20Michael%22%2C%22lastName%22%3A%22Deeb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Blas%5Cu00e9%22%2C%22lastName%22%3A%22Carabello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20W.%22%2C%22lastName%22%3A%22Serruys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sharla%22%2C%22lastName%22%3A%22Chenoweth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jae%20K.%22%2C%22lastName%22%3A%22Oh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22CoreValve%20United%20States%20Clinical%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20This%20study%20sought%20to%20evaluate%20the%20safety%20and%20efficacy%20of%20the%20CoreValve%20transcatheter%20heart%20valve%20%28THV%29%20for%20the%20treatment%20of%20severe%20aortic%20stenosis%20in%20patients%20at%20extreme%20risk%20for%20surgery.%5CnBACKGROUND%3A%20Untreated%20severe%20aortic%20stenosis%20is%20a%20progressive%20disease%20with%20a%20poor%20prognosis.%20Transcatheter%20aortic%20valve%20replacement%20%28TAVR%29%20with%20a%20self-expanding%20bioprosthesis%20is%20a%20potentially%20effective%20therapy.%5CnMETHODS%3A%20We%20performed%20a%20prospective%2C%20multicenter%2C%20nonrandomized%20investigation%20evaluating%20the%20safety%20and%20efficacy%20of%20self-expanding%20TAVR%20in%20patients%20with%20symptomatic%20severe%20aortic%20stenosis%20with%20prohibitive%20risks%20for%20surgery.%20The%20primary%20endpoint%20was%20a%20composite%20of%20all-cause%20mortality%20or%20major%20stroke%20at%2012%20months%2C%20which%20was%20compared%20with%20a%20pre-specified%20objective%20performance%20goal%20%28OPG%29.%5CnRESULTS%3A%20A%20total%20of%2041%20sites%20in%20the%20United%20States%20recruited%20506%20patients%2C%20of%20whom%20489%20underwent%20attempted%20treatment%20with%20the%20CoreValve%20THV.%20The%20rate%20of%20all-cause%20mortality%20or%20major%20stroke%20at%2012%20months%20was%2026.0%25%20%28upper%202-sided%2095%25%20confidence%20bound%3A%2029.9%25%29%20versus%2043.0%25%20with%20the%20OPG%20%28p%20%26lt%3B%200.0001%29.%20Individual%2030-day%20and%2012-month%20events%20included%20all-cause%20mortality%20%288.4%25%20and%2024.3%25%2C%20respectively%29%20and%20major%20stroke%20%282.3%25%20and%204.3%25%2C%20respectively%29.%20Procedural%20events%20at%2030%20days%20included%20life-threatening%5C%2Fdisabling%20bleeding%20%2812.7%25%29%2C%20major%20vascular%20complications%20%288.2%25%29%2C%20and%20need%20for%20permanent%20pacemaker%20placement%20%2821.6%25%29.%20The%20frequency%20of%20moderate%20or%20severe%20paravalvular%20aortic%20regurgitation%20was%20lower%2012%20months%20after%20self-expanding%20TAVR%20%284.2%25%29%20than%20at%20discharge%20%2810.7%25%3B%20p%20%3D%200.004%20for%20paired%20analysis%29.%5CnCONCLUSIONS%3A%20TAVR%20with%20a%20self-expanding%20bioprosthesis%20was%20safe%20and%20effective%20in%20patients%20with%20symptomatic%20severe%20aortic%20stenosis%20at%20prohibitive%20risk%20for%20surgical%20valve%20replacement.%20%28Safety%20and%20Efficacy%20Study%20of%20the%20Medtronic%20CoreValve%20System%20in%20the%20Treatment%20of%20Symptomatic%20Severe%20Aortic%20Stenosis%20in%20High%20Risk%20and%20Very%20High%20Risk%20Subjects%20Who%20Need%20Aortic%20Valve%20Replacement%3B%20NCT01240902%29.%22%2C%22date%22%3A%22May%2020%2C%202014%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jacc.2014.02.556%22%2C%22ISSN%22%3A%221558-3597%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22BJSZ96GT%22%2C%22YL3LPZGE%22%2C%22B2JSS4XR%22%2C%22N5HQ4VYL%22%5D%2C%22dateModified%22%3A%222022-03-08T19%3A34%3A33Z%22%7D%7D%2C%7B%22key%22%3A%22ADU3IYIB%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Weeks%20et%20al.%22%2C%22parsedDate%22%3A%222013-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BWeeks%2C%20P.%20A.%2C%20Alkhateeb%2C%20H.%20M.%2C%20Michaud%2C%20S.%20E.%20et%20al.%20%282013%29.%20Evaluation%20of%20bivalirudin%20hyper-%20and%20hypo-ACT%20responses%20in%20the%20setting%20of%20percutaneous%20coronary%20intervention.%20%26lt%3Bi%26gt%3BJ%20Invasive%20Cardiol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B25%26lt%3B%5C%2Fi%26gt%3B%2C%20250%26%23x2013%3B253%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evaluation%20of%20bivalirudin%20hyper-%20and%20hypo-ACT%20responses%20in%20the%20setting%20of%20percutaneous%20coronary%20intervention%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Phillip%20A.%22%2C%22lastName%22%3A%22Weeks%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Haider%20M.%22%2C%22lastName%22%3A%22Alkhateeb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%20E.%22%2C%22lastName%22%3A%22Michaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20G.%22%2C%22lastName%22%3A%22Diez%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Bivalirudin%20has%20emerged%20as%20a%20suitable%20alternative%20anticoagulant%20to%20unfractionated%20heparin%20and%20low-molecular-weight%20heparins%20during%20percutaneous%20coronary%20intervention%20%28PCI%29%20procedures%20in%20the%20management%20of%20coronary%20artery%20disease%20and%20acute%20coronary%20syndromes%20%28ACS%29.%20In%20clinical%20trials%2C%20bivalirudin%20dosing%20was%20standardized%2C%20and%20activated%20clotting%20time%20%28ACT%29%20did%20not%20influence%20dosing%20adjustments.%20The%20role%20of%20ACT%20monitoring%20of%20bivalirudin%20in%20PCI%20is%20not%20defined%20based%20on%20current%20practice%20guidelines.%5CnHYPOTHESIS%3A%20The%20hypothesis%20of%20this%20study%20is%20that%20hyper-%20and%20hypo-ACT%20responses%20to%20bivalirudin%20in%20PCI%20may%20be%20associated%20with%20excessive%20bleeding%20or%20thrombotic%20complications.%5CnMETHODS%3A%20The%20planned%20protocol%20screened%20all%20patients%20who%20received%20bivalirudin%20therapy%20and%20ACT%20monitoring%20during%20PCI%20in%20a%20single%20center%26%23039%3Bs%20cardiac%20catheterization%20laboratory%20from%20July%202009%20to%20June%202010.%20The%20first%20ACT%20monitored%205%20to%2060%20minutes%20after%20bivalirudin%20initiation%20was%20screened%20for%20inclusion.%20Values%20above%20800%20seconds%20and%20below%20300%20seconds%20were%20included%20as%20hyper-%20and%20hypo-ACT%20responses%2C%20respectively.%20Outcomes%20assessed%20include%20thrombotic%20and%20bleeding%20complications.%5CnRESULTS%3A%20There%20were%2032%20patients%20identified%20as%20hyper-responders%20and%2020%20patients%20identified%20as%20hypo-responders.%20There%20were%20no%20significant%20thrombotic%20or%20bleeding%20complications%20in%20the%20hyper-responder%20group.%20There%20was%201%20case%20%281%5C%2F20%2C%205%25%29%20of%20angiographically%20confirmed%20acute%20stent%20thrombosis%20immediately%20following%20the%20placement%20of%205%20adjoining%20bare-metal%20stents%20in%20the%20right%20coronary%20artery%20of%20a%20hypo-responder.%5CnCONCLUSIONS%3A%20Hyper-ACT%20responses%20to%20bivalirudin%20therapy%20in%20PCI%20were%20not%20associated%20with%20additional%20bleeding%20risk.%20Bivalirudin%20may%20not%20adequately%20protect%20hypo-ACT%20responders%20against%20thrombotic%20complications%20during%20PCI.%22%2C%22date%22%3A%22May%202013%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%221557-2501%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22YL3LPZGE%22%5D%2C%22dateModified%22%3A%222022-01-25T18%3A50%3A45Z%22%7D%7D%5D%7D

Hong, J.C., Orozco-Sevilla, V., Diez, J.G. et al. (2023). Transkateter aortaklap-i-ventil-i-klap udskiftning hos en ung kvinde med transkateterstrukturel klapforringelse inden for et degenereret aortarodshomograft. Tex Heart Inst J 50, e227874. https://doi.org/10.14503/THIJ-22-7874.

Farmer, D. M., Díez, J. G., Orozco-Sevilla, V. et al. (2022). Brug af en selvekspanderende transkateterventil til en degenereret INTUITY-ventil. J Card Surg. https://doi.org/10.1111/jocs.16746.

Kherallah, RY, Koneru, S., Krajcer, Z. et al. (2021). Hæmodynamiske resultater efter ventil-i-ventil transkateter-aortaklapudskiftning: en enkeltcenteroplevelse. Ann Cardiothorac Surg 10, 630-640. https://doi.org/10.21037/acs-2021-tviv-131.

Cekmecelioglu, D., Preventza, O., Dougherty, K.G. et al. (2021). Transkateter ventil-i-ventil implantation til degenererede stentløse aorta-biorødder. Ann Cardiothorac Surg 10, 641-650. https://doi.org/10.21037/acs-2021-tviv-124.

Kleiman, N.S., Maini, B.J., Reardon, M.J. et al. (2016). Neurologiske hændelser efter udskiftning af transkateter aortaklap og deres forudsigelser: en rapport fra corevalve-forsøgene. Circ Cardiovasc Interv 9. https://doi.org/10.1161/CIRCINTERVENTIONS.115.003551.

Díez, J.G., Schechter, M., Dougherty, K.G. et al. (2016). Transkateter aortaklap-i-klap udskiftning i stedet for en 4. sternotomi hos en 21-årig kvinde med aorta homograft svigt. Tex Heart Inst J 43, 334-337. https://doi.org/10.14503/THIJ-15-5128.

Yakubov, S.J., Adams, D.H., Watson, D.R. et al. (2015). 2-års resultater efter Iliofemoral selvekspanderende transkateter-aortaklapudskiftning hos patienter med svær aortastenose, der anses for at være ekstrem risiko for kirurgi. J er Coll Cardiol 66, 1327-1334. https://doi.org/10.1016/j.jacc.2015.07.042.

Lombo, B., Alkhalil, I., Golden, M.P. et al. (2015). Forekomst af metabolisk syndrom hos patienter med HIV i en tid med højaktiv antiretroviral terapi. Conn Med 79, 277-281

Popma, J.J., Adams, D.H., Reardon, M.J. et al. (2014). Transkateter udskiftning af aortaklap ved hjælp af en selvekspanderende bioprotese hos patienter med svær aortastenose med ekstrem risiko for operation. J er Coll Cardiol 63, 1972-1981. https://doi.org/10.1016/j.jacc.2014.02.556.

Weeks, P.A., Alkhateeb, H.M., Michaud, S.E. et al. (2013). Evaluering af bivalirudin hyper- og hypo-ACT-responser i forbindelse med perkutan koronar intervention. J Invasiv Cardiol 25, 250-253